PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 c... PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.28 | -5.71428571429 | 4.9 | 4.94 | 4.4 | 101564 | 4.54084378 | CS |
| 4 | 0.32 | 7.44186046512 | 4.3 | 5.21 | 4.25 | 167973 | 4.78690468 | CS |
| 12 | 0.27 | 6.20689655172 | 4.35 | 5.21 | 4.03 | 91091 | 4.64033638 | CS |
| 26 | 0.65 | 16.3727959698 | 3.97 | 5.21 | 3.89 | 75495 | 4.53772071 | CS |
| 52 | 1.17 | 33.9130434783 | 3.45 | 5.21 | 3.06 | 89370 | 3.97248859 | CS |
| 156 | 4.2002 | 1000.52405908 | 0.4198 | 9.2 | 0.2006 | 78827 | 3.22372912 | CS |
| 260 | -4.76 | -50.7462686567 | 9.38 | 9.64 | 0.2006 | 129498 | 2.3184492 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。